Advertisement
Advertisement

PCRX

PCRX logo

Pacira BioSciences, Inc. Common Stock

23.96
USD
Sponsored
+0.45
+1.91%
Jun 24, 16:00 UTC -4
Closed
exchange

After-Market

23.97

+0.01
+0.04%

PCRX Earnings Reports

Positive Surprise Ratio

PCRX beat 27 of 42 last estimates.

64%

Next Report

Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$194.63M
/
$0.66
Implied change from Q1 26 (Revenue/ EPS)
+9.73%
/
+10.00%
Implied change from Q2 25 (Revenue/ EPS)
+7.47%
/
-10.81%

Pacira BioSciences, Inc. Common Stock earnings per share and revenue

On Apr 30, 2026, PCRX reported earnings of 0.60 USD per share (EPS) for Q1 26, beating the estimate of 0.57 USD, resulting in a 4.42% surprise. Revenue reached 177.38 million, compared to an expected 176.79 million, with a 0.33% difference. The market reacted with a -4.12% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of 0.66 USD, with revenue projected to reach 194.63 million USD, implying an increase of 10.00% EPS, and increase of 9.73% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
logo
Prenetics Global Limited Class A Ordinary Share
Report Date
Jun 10, 2026 For Q1 26
Estimate
-$1.10
Actual
-$1.61
Surprise
-45.36%
logo
Anixa Biosciences, Inc.
Report Date
Jun 10, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+21.61%
logo
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
For Q1 2026, Pacira BioSciences, Inc. Common Stock reported EPS of $0.60, beating estimates by 4.42%, and revenue of $177.38M, 0.33% above expectations.
The stock price moved down -4.12%, changed from $25.49 before the earnings release to $24.44 the day after.
The next earning report is scheduled for Aug 03, 2026.
Based on 5 analysts, Pacira BioSciences, Inc. Common Stock is expected to report EPS of $0.66 and revenue of $194.63M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement